Novo Nordisk A/S
LSE:0QIU
Relative Value
The Relative Value of one
0QIU
stock under the Base Case scenario is
hidden
DKK.
Compared to the current market price of 373.775 DKK,
Novo Nordisk A/S
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
0QIU Competitors Multiples
Novo Nordisk A/S Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
LSE:0QIU
|
1.4T DKK | 4.3 | 13.1 | 9.2 | 10.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD | 17.7 | 57 | 38.2 | 41 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD | 6 | 21.1 | 14.7 | 18 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
287.9B CHF | 4.7 | 30.7 | 12.9 | 15.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD | 4.6 | 15.5 | 10.9 | 12.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.6B CHF | 5.3 | 20.5 | 12.9 | 16.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215B GBP | 5.1 | 31.6 | 15.1 | 22.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD | 2.4 | 15.6 | 7.8 | 10.7 | |
| FR |
|
Sanofi SA
PAR:SAN
|
98.9B EUR | 1.8 | 8.3 | 7.7 | 7.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 2.4 | 19.4 | 6.9 | 9 |